Journal Article

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

Rivellese, Felice, Warren, Sarah E., Goldmann, Katriona, Çubuk, Cankut, McKeigue, Paul M., Church, Sarah E., Thorborn, Georgina, Pitzalis, Costantino, Fossati-Jimack, Liliane, Surace, Anna E. A., Barnes, Michael R., Sciacca, Elisabetta, John, Christopher R., Nerviani, Alessandra, Hudson, Briana M., Humby, Frances, Ahmed, Manzoor, Prediletto, Edoardo, Bombardieri, Michele, Giorli, Giovanni, Lewis, Myles J.

2022

Overview

Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5–20% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n  = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response/nonresponse remain to be established. Here, in-depth histological/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal/fibroblast signature in patients refractory to all medications. Post-treatment changes in synovial gene expression and cell infiltration highlighted divergent effects of rituximab and tocilizumab relating to differing response/nonresponse mechanisms. Using ten-by-tenfold nested cross-validation, we developed machine learning algorithms predictive of response to rituximab (area under the curve (AUC) = 0.74), tocilizumab (AUC = 0.68) and, notably, multidrug resistance (AUC = 0.69). This study supports the notion that disease endotypes, driven by diverse molecular pathology pathways in the diseased tissue, determine diverse clinical and treatment–response phenotypes. It also highlights the importance of integration of molecular pathology signatures into clinical algorithms to optimize the future use of existing medications and inform the development of new drugs for refractory patients. Biomarker analysis of the phase 4 R4RA trial identifies pretreatment synovial biopsy features selectively associated with response to rituximab or tocilizumab, and leads to the development of models that might predict treatment benefit in patients with rheumatoid arthritis

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 631/114/1305 / 631/114/2413 / 692/308/2779/777 / 692/308/53/2423 / 692/699/1670/498 / Algorithms / Antibodies, Monoclonal - therapeutic use / Antibodies, Monoclonal, Humanized / Antirheumatic Agents - therapeutic use / Arthritis / Arthritis, Rheumatoid - drug therapy / Arthritis, Rheumatoid - genetics / Autoimmune diseases / Biomarkers / Biomarkers - analysis / Biomedical and Life Sciences / Biomedicine / Biopsy / Cancer Research / CD20 antigen / Divergence / Drug development / Gene expression / Health services / Humans / Immune response / Immune response (humoral) / Immunosuppressive agents / Immunotherapy / Infectious Diseases / Interleukin 6 / Interleukin 6 receptors / Machine learning / Metabolic Diseases / Molecular Medicine / Monoclonal antibodies / Multidrug resistance / Neurosciences / Pathology / Patients / Phenotypes / Rheumatoid arthritis / Rituximab / Rituximab - therapeutic use